Enterprise Value
400.6M
Cash
173M
Avg Qtr Burn
-2.705M
Short % of Float
8.03%
Insider Ownership
21.22%
Institutional Own.
71.68%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
WVE-N531 Details Duchenne muscular dystrophy | Phase 1/2 Data readout | |
WVE-003 Details Huntington's disease | Phase 1/2 Data readout | |
WVE-120101 (SNP1) Details Huntington's disease | Failed Discontinued | |
WVE-120102 (SNP2) Details Huntington's disease | Failed Discontinued | |
WVE-004 Details Amyotrophic lateral sclerosis, Frontotemporal dementia with GRN mutations | Failed Discontinued |